Medicine and research reference
Survodutide
The identity and selected clinical evidence for survodutide, with completion and tolerability limits.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
What it is
Survodutide, also called BI 456906, is a glucagon and GLP-1 receptor dual agonist investigated in metabolic disease. Its name identifies a particular molecule, not a general category of weight-management peptides.
Sources: le Roux and colleagues, The Lancet Diabetes & Endocrinology; indexed by PubMed
Reading the trial
A 2024 phase 2 report studied adults without diabetes across 12 countries. Of 386 treated participants, about 60% completed the 46-week treatment period. Average weight reductions were greater with survodutide than placebo. Completion rates and the analysis used matter when interpreting that result. Boehringer Ingelheim funded the trial; its indexed record also links a subsequent correction.
Sources: le Roux and colleagues, The Lancet Diabetes & Endocrinology; indexed by PubMed
Tolerability and product scope
Gastrointestinal events occurred in 75% of survodutide recipients versus 42% of placebo recipients. Study findings are specific to the controlled trial and cannot establish the quality of a separately supplied powder.
Sources: le Roux and colleagues, The Lancet Diabetes & Endocrinology; indexed by PubMed
FDA has warned about unapproved products containing survodutide sold to consumers under research-use labels. Such a label is not a clinical assessment.
Sources: U.S. Food and Drug Administration
Published sources
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux and colleagues, The Lancet Diabetes & Endocrinology; indexed by PubMed. Published 5 February 2024 online; record links a subsequent correction; accessed 6 September 2026.
Supports: Dual-receptor identity, study population, completion and gastrointestinal adverse events. Selected trial, not a complete development history.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: U.S. status of retatrutide and cagrilintide and concerns about unapproved products sold for human use.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.